Spyre Therapeutics, Inc.

US$103.86As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SYREHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (2.51%)
Div yield —
ROE (35.03%)
Biotechnology
Beta (5Y) 3.23
PE TTM —
TSR TTM 324.61%
Mkt cap US$9.863B
ROIC (26.56%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$128
22.92%
(57.51%)
Hold 1|12|1|8|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.86
0.90
0.92
0.99
(7.25%)
1.27%
5.55%
11.19%
Revenue$M
488.9
484.6
492.4
500.3
(5.90%)
(4.45%)
(0.24%)
0.01%
Peers (US$9.863B)
Cap (US$)
PE
10.11B
—
9.152B
—
Capital
TTM
5Y
10Y
Leveragex
0.554
(0.395)
(0.394)
EBIT/Intx
11.69
0.684
0.470
Own earn%
98.49
97.38
79.32
Sh yield%
20.43
42.89
44.25
Owners
Insiders/Inst%
14.38
37.05
Short interest%
0.66
SBC / revenue%
3.77
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
14
Op margin range%
19–24
$1 testx
0.3
Incr. ROIC%
4